Subscribe to Newsletter
Diagnostics Genetics and epigenetics, Oncology, Technology and innovation, COVID-19

Business in Brief

Making a Mark

A PCR-based test for determining microsatellite instability (MSI) status in solid tumors has received the CE mark as a new in vitro diagnostic medical device. OncoMate™ MSI provides a DNA-based MSI reading complementary to a standard MMR immunohistochemistry panel, which can be used to predict response to immuno-oncology therapies (1).

Spying a Treatment

Quantum Leap Healthcare Collaborative has selected Byondis B.V.’s investigational antibody-drug conjugate, SYD985, in its ongoing I-SPY 2 TRIAL™ for neoadjuvant breast cancer treatment. The trial aims to rapidly screen and identify promising treatments in specific subgroups of women with newly diagnosed, high-risk, and locally advanced cancer (2).

To the Bone

A new type of predictive test for osteoporosis provides early insights into the bone mineral balance of the human body using a urine or blood sample. In a study of 100 women, the OsteoTest predicted fractures caused by bone atrophy more accurately and less invasively than current X-ray-based methods (3).

Going Viral

Beckman Coulter’s Access SARS-CoV-2 IgG assay has received Emergency Use Authorization from the US Food and Drug Administration. The assay, which is in over 400 hospitals, clinics, and diagnostic laboratories in the US, will now be distributed worldwide – and the company says it can produce over 30 million tests every month (4).

Genetic Targets

An analysis of 929 genomes from patients who responded poorly to COVID-19 has revealed 68 genes associated with severe disease. Researchers hope the genes – nine of which are already targets of drugs that have reached at least Phase I clinical trials – will inform the development of biomarker-driven tests and new therapeutic strategies (5).

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Promega (2020). Available at:
  2. Byondis (2020). Available at:
  3. Osteolabs (2020). Available at:
  4. Beckman Coulter (2020). Available at:
  5. S Ghafouri-Fard et al., 128, 110296 (2020). PMID: 32480226.
About the Author
Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine